Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection Against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2008 Apr 4

PMID 18385248

Citations 88

Authors

Thomas W Geisbert

Kathleen M Daddario-DiCaprio

Kinola J N Williams

Joan B Geisbert

Anders Leung

Friederike Feldmann

Lisa E Hensley

Heinz Feldmann

Steven M Jones

Affiliations

Soon will be listed here.

Abstract

Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus. Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after exposure to SEBOV. All four animals survived SEBOV challenge, while a control animal that received a nonspecific vector developed fulminant SEBOV hemorrhagic fever and succumbed. This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses.

Citing Articles

An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.

de La Vega M, Xiii A, Massey S, Spengler J, Kobinger G, Woolsey C Expert Opin Drug Discov. 2024; 19(10):1185-1211.

PMID: 39090822 PMC: 11466704. DOI: 10.1080/17460441.2024.2386100.

High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.

Todesco H, Gafuik C, John C, Roberts E, Borys B, Pawluk A Mol Ther Methods Clin Dev. 2024; 32(1):101189.

PMID: 38327804 PMC: 10847022. DOI: 10.1016/j.omtm.2024.101189.

Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.

Bushmaker T, Feldmann F, Lovaglio J, Saturday G, Griffin A, ODonnell K J Infect Dis. 2023; 228(Suppl 7):S721-S729.

PMID: 37474155 PMC: 10651186. DOI: 10.1093/infdis/jiad280.

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs.

Cao W, He S, Liu G, Schulz H, Emeterio K, Chan M NPJ Vaccines. 2023; 8(1):91.

PMID: 37301890 PMC: 10257645. DOI: 10.1038/s41541-023-00685-z.

A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.

Woolsey C, Strampe J, Fenton K, Agans K, Martinez J, Borisevich V J Infect Dis. 2023; 228(Suppl 7):S712-S720.

PMID: 37290053 PMC: 10651203. DOI: 10.1093/infdis/jiad207.

References

Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A . Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998; 251(1):28-37. DOI: 10.1006/viro.1998.9367. View

Sullivan N, Sanchez A, Rollin P, Yang Z, Nabel G . Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812):605-9. DOI: 10.1038/35046108. View

Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78(10):5458-65. PMC: 400370. DOI: 10.1128/jvi.78.10.5458-5465.2004. View

Sullivan N, Geisbert T, Geisbert J, Shedlock D, Xu L, Lamoreaux L . Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006; 3(6):e177. PMC: 1459482. DOI: 10.1371/journal.pmed.0030177. View

Sullivan N, Geisbert T, Geisbert J, Xu L, Yang Z, Roederer M . Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003; 424(6949):681-4. PMC: 7095492. DOI: 10.1038/nature01876. View

Warfield K, Swenson D, Olinger G, Kalina W, Aman M, Bavari S . Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007; 196 Suppl 2:S430-7. DOI: 10.1086/520583. View

Geisbert T, Hensley L, Kagan E, Yu E, Geisbert J, Daddario-DiCaprio K . Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006; 193(12):1650-7. PMC: 7110204. DOI: 10.1086/504267. View

Daddario-DiCaprio K, Geisbert T, Stroher U, Geisbert J, Grolla A, Fritz E . Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006; 367(9520):1399-404. DOI: 10.1016/S0140-6736(06)68546-2. View

Enterlein S, Warfield K, Swenson D, Stein D, Smith J, Gamble C . VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006; 50(3):984-93. PMC: 1426423. DOI: 10.1128/AAC.50.3.984-993.2006. View

10.

Jones S, Feldmann H, Stroher U, Geisbert J, Fernando L, Grolla A . Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7):786-90. DOI: 10.1038/nm1258. View

11.

ELLIS D, BOWEN E, Simpson D, Stamford S . Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys. Br J Exp Pathol. 1978; 59(6):584-93. PMC: 2041404. View

12.

Feldmann H, Jones S, Daddario-DiCaprio K, Geisbert J, Stroher U, Grolla A . Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007; 3(1):e2. PMC: 1779298. DOI: 10.1371/journal.ppat.0030002. View

13.

Warfield K, Swenson D, Olinger G, Nichols D, Pratt W, Blouch R . Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006; 2(1):e1. PMC: 1326218. DOI: 10.1371/journal.ppat.0020001. View

14.

Hensley L, Stevens E, Yan S, Geisbert J, Macias W, Larsen T . Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007; 196 Suppl 2:S390-9. DOI: 10.1086/520598. View

15.

Geisbert T, Daddario-DiCaprio K, Geisbert J, Young H, Formenty P, Fritz E . Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis. 2007; 196 Suppl 2:S372-81. PMC: 7110112. DOI: 10.1086/520608. View

16.

Geisbert T, Hensley L, Jahrling P, Larsen T, Geisbert J, Paragas J . Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003; 362(9400):1953-8. DOI: 10.1016/S0140-6736(03)15012-X. View

17.

Bukreyev A, Rollin P, Tate M, Yang L, Zaki S, Shieh W . Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007; 81(12):6379-88. PMC: 1900097. DOI: 10.1128/JVI.00105-07. View

18.

Daddario-DiCaprio K, Geisbert T, Geisbert J, Stroher U, Hensley L, Grolla A . Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006; 80(19):9659-66. PMC: 1617222. DOI: 10.1128/JVI.00959-06. View

19.

Alsop Z . Ebola outbreak in Uganda "atypical", say experts. Lancet. 2007; 370(9605):2085. DOI: 10.1016/s0140-6736(07)61880-7. View